Therapeutics Company Acquires Cord Blood Banking Licence and Assets

CytoMed Therapeutics Limited (NASDAQ: GDTC), a Singapore-based biopharmaceutical company, has recently made a acquisition aimed at bolstering its position in the allogeneic, off-the-shelf donor-derived gamma delta (γδ) T cells technology sector. Through its wholly-owned subsidiary, IPSC Depository Sdn Bhd, CytoMed has acquired the licence and certain assets of Cellsafe International Sdn Bhd (In Liquidation) (“CISB”), a Malaysian cord blood bank. This acquisition, valued at approximately RM 2.3 million or US$ 490,000, was funded from CytoMed's internal cash resources. $CytoMed Therapeutics (GDTC.US)$